FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Conditions
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Trial Timeline
Dec 1, 2007 → Dec 1, 2008
NCT ID
NCT00576420About FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time
FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time is a phase 2 stage product being developed by Baxter for Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts). The current trial status is completed. This product is registered under clinical trial identifier NCT00576420. Target conditions include Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00576420 | Phase 2 | Completed |
Competing Products
4 competing products in Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TISSEEL Lyo | Baxter | Phase 3 | 74 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2 | 47 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |